Identification of B‑cell translocation gene 1‑controlled gene networks in diffuse large B‑cell lymphoma: A study based on bioinformatics analysis

Abstract

B-cell translocation gene 1 (BTG1) is a member of the BTG/transducer of Erb family. The present study evaluated the impact of BTG1 gene expression on the clinical outcome of diffuse large B-cell lymphoma (DLBCL) and investigated potential mechanisms using the Gene Expression Omnibus (GEO) database. The gene expression profile datasets GSE31312, GSE10846, GSE65420 and GSE87371 were downloaded from the GEO database. BTG1 expression and clinicopathological data were obtained from the GSE31312 dataset. In 498 cases, the expression of BTG1 in DLBCL was associated with treatment response (χ 2 =19.020; P<0.001) and International Prognostic Index score (χ 2 =5.320; P=0.025). Using the Kaplan-Meier method, it was identified that the expression of BTG1 was associated with overall survival (OS) and progression-free survival (PFS) times. Univariate and multivariate Cox regression analysis demonstrated that BTG1 was an independent predictive factor for OS and PFS. From the overlapping analysis of 407 BTG1-associated genes and 22,187 DLBCL-associated genes, 401 genes were identified as BTG1-associated DLBCL genes. Pathway analysis revealed that BTG1-associated DLBCL genes were associated with cancer progression and DLBCL signaling pathways. Subsequently, a protein-protein interaction network was constructed of the BTG1-associated genes, which consisted of 235 genes and 601 interactions. Additionally, 24 genes with high degrees in the network were identified as hub genes, which included genes associated with ‘ribosome’ [ribosomal protein (RP) L11, RPL3, RPS29, RPL19, RPL15 and RPL12], ‘cell cycle’ (ubiquitin carboxyl extension protein 52, ATM and Ras homolog family member H), ‘mitogen-activated protein kinase pathway’ (mitogen-activated protein kinase 1), ‘histone modification’ (ASH1-like protein) and ‘transcription/translation’ (eukaryotic translation initiation factor 3 subunit E, eukaryotic translation elongation factor 1 δ, transcription termination factor 1, cAMP responsive element binding protein 1 and RNA polymerase II subunit F). In conclusion, BTG1 may serve as a predictive biomarker for DLBCL prognosis. Additionally, bioinformatics analysis indicated that BTG1 may exhibit key functions in the progression and development of DLBCL.

Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche

“…In the current study we provide the first characterization of BM FL B cell GEP and confirmed their quiescent phenotype, associated with the upregulation of the antiproliferative gene BTG1. Interestingly, a BTG1 hi phenotype was recently associated with a good prognosis in aggressive DLBCL 52 , in association with a decreased cell cycle, confirming a role for BTG1 in the regulation of cell proliferation in GC-derived B-cell lymphomas. The analysis of the interactome between BM FL B cells and EVs-primed BM-MSC highlights not only CXCL12 but also Eph/ephrin pathway.…”

RPL19 Is a Prognostic Biomarker and Promotes Tumor Progression in Hepatocellular Carcinoma

“…The four hub genes we discovered have been studied in multiple tumors. RPL19, which is a tumor-specific antigen of lung adenocarcinoma ( Kuroda et al, 2010 ), can also be used as a prognostic biomarker for prostate cancer ( Bee et al, 2006 ), colorectal cancer ( Huang et al, 2008 ), and diffuse large B-cell lymphoma ( Yan et al, 2019 ). One study ( Bee et al, 2006 ) proposed that the expression of RPL19 in malignant prostate cancer cells was significantly higher than that in prostate cells.…”

The role of EEF1D in disease pathogenesis: a narrative review

“…The overexpression of EEF1D has been identified in glioblastoma, glioma, prostate cancer, colorectal cancer (11), renal papillary cell carcinoma (12), liver cancer (13), oral squamous cell carcinoma ( 14), esophageal cancer (15), and medulloblastoma (16). Furthermore, it has also been found to be significantly overexpressed in 10 different lymphoma isoforms (17). One study confirmed that a high EEF1D mRNA level is associated with lymph node metastasis, advanced stage, and shorter disease-specific survival in patients with esophageal cancer (15).…”

“…Similar results have also been demonstrated in gastrointestinal cancer (18). However, it is worth noting that the mRNA level of EEF1D in pancreatic cancer shows the opposite trend (17), and the specificreasons for this need to be further explored (Table 1).…”